PharmaLogic: Lantheus CDMO Acquisition Expands Radiopharmaceutical Manufacturing Capacity In New Jersey

PharmaLogic Holdings has entered into an agreement to acquire Lantheus’ contract development and manufacturing business and its Springfield, New Jersey manufacturing facility. The transaction will expand PharmaLogic’s U.S. radiopharmaceutical manufacturing capabilities and strengthen the transatlantic infrastructure of its therapeutic CDMO business, Agilera.

The acquisition includes an established manufacturing operation supporting radiopharmaceutical research, development, and commercial production.

The Springfield facility has capabilities involving theranostic products, which connect targeted diagnostic imaging with therapeutic applications.

Radiopharmaceuticals use radioactive materials in diagnostic or therapeutic products.

Their development and manufacturing can require specialized facilities, technical expertise, quality controls, and distribution capabilities.

The Springfield site will become part of Agilera following completion of the transaction.

Employees associated with the facility will join the Agilera organization.

The acquisition will also include a long-term supply arrangement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.

The agreement is intended to maintain access to manufacturing services for Lantheus while allowing PharmaLogic to expand its therapeutic production business.

Agilera has more than 15 years of experience supporting the development and commercial introduction of radioligand therapies.

The business currently supplies an alpha-emitting therapeutic product to more than 30 countries.

Adding the Springfield operation will extend its manufacturing presence in the United States.

PharmaLogic believes the combination will establish a differentiated transatlantic platform for therapeutic radiopharmaceutical contract development and manufacturing.

The company intends to support customers across the product lifecycle, from early clinical research to commercial launch and international supply.

Manufacturing radiopharmaceutical therapies can involve challenges related to radioactive material handling, production timing, specialized transportation, and strict regulatory requirements.

These requirements create demand for manufacturing partners with established technical capabilities and regulatory experience.

PharmaLogic sees opportunities to address these needs through the addition of U.S. manufacturing capacity and its existing international operations.

The company operates more than 45 facilities across the United States, Puerto Rico, Canada, and Norway.

Its broader business provides radiopharmaceutical development, manufacturing, and distribution services for both diagnostic and therapeutic applications.

In diagnostics, the company supports products used in oncology, cardiology, and neurology.

Its therapeutic business focuses on manufacturing radiopharmaceutical treatments for customers seeking specialized production capabilities.

The acquisition strengthens PharmaLogic’s ability to serve companies developing radioligand therapies that require both technical development and commercial manufacturing.

For Lantheus, the transaction transfers ownership of the Springfield facility to a company specializing in radiopharmaceutical contract manufacturing.

Lantheus will retain a commercial relationship through the long-term supply agreement.

The companies have worked together previously, with PharmaLogic providing manufacturing support for Lantheus’ PET diagnostic products.

That established relationship is expected to support the transition.

The transaction remains subject to applicable regulatory reviews and customary closing requirements.

Until completion, PharmaLogic and Lantheus will continue operating independently.

Leerink Partners served as financial advisor to PharmaLogic, while Goodwin provided legal counsel.

Solomon Partners advised Lantheus, with Covington & Burling providing legal advice.

The acquisition positions PharmaLogic to expand its role in therapeutic radiopharmaceutical manufacturing by combining an established U.S. facility with its existing international development and production network.

KEY QUOTES:

“This acquisition strengthens Agilera’s unique capabilities in radioligand therapies and expands our capacity in the U.S. We are proud to welcome the talented Springfield team, who will help us scale our operations to meet growing demand from our partners and the patients they serve.”

Etienne Montagut, President And CEO Of PharmaLogic

“We have a long-standing relationship with PharmaLogic, which has been an important manufacturing partner for our PET products. With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on this foundation while supporting reliable supply of our newly approved radiotherapeutic for patients and healthcare providers.”

Mary Anne Heino, Executive Chairperson And CEO Of Lantheus